Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
10.09.2026 04:02
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
10.09.2026 02:27
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
09.09.2026 15:14
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
09.09.2026 15:00
MENLO PARK, Calif., September 09, 2026--Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges
09.09.2026 13:54
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Gilead launches research facility in US for new medicine development
09.09.2026 10:59
The new research centre is part of Gilead's strategy to advance US research, development and manufacturing through 2030.
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
09.09.2026 10:15
MacroGenics (MGNX) trades below cash with a strong ADC/TCE pipeline and ESMO 2026 catalysts.
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?
08.09.2026 00:45
Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead’s (NASDAQ:GILD) blockbuster Biktarvy, and lenacapavir, the foundation of the company’s longer-term HIV strategy. […]
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
04.09.2026 17:08
Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
04.09.2026 15:30
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
04.09.2026 14:45
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
04.09.2026 10:21
Gilead Sciences offers a 3.98% dividend yield backed by strong profitability and a solid track record, meeting key quality, health, and income criteria.
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
04.09.2026 10:10
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
FDA Approves Gilead's New Single Tablet HIV Regimen
31.08.2026 13:38
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
16.08.2026 08:00
Assembly Biosciences' key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC. Read why ASMB stock is a Buy.
Why Gilead Sciences (GILD) Is Back In The Spotlight
13.08.2026 09:11
Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder returns are above 90%...
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
13.08.2026 04:21
Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches—including Trodelvy in breast cancer and Livdelzi in liver disease—for boosting results. CEO Daniel O’Day highlighted, “Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,” underscoring the im
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
07.08.2026 14:00
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
06.08.2026 11:04
This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches.
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...
05.08.2026 05:06
Gilead delivers strongest Q2 base business growth in 3 years, raises full-year HIV guidance, and showcases rapid uptake of Yeztugo and Trodelvy despite acquisition-related EPS drag.